Technivie复方治疗基因型4慢性丙型肝炎

发布时间：2018-06-21 01:03

  本文选题：Technivie + 慢性丙型肝炎　； 参考：《国际药学研究杂志》2015年05期

【摘要】：正Technivie是翁比他韦(ombitasvir)、帕利普韦(paritaprevir)及利托那韦(ritonavir)固定剂量组合片剂,前者为HCV NS5A抑制剂,中间为HCV NS3/4A蛋白酶抑制剂,后者为CYP3A抑制剂。其与利巴韦林联合,专用于治疗无肝硬化的基因型4慢性丙型肝炎病毒(HCV)感染。推荐剂量是每日早餐时口服1次,2片/次,持
[Abstract]:Positive Technivie is a fixed dose combination tablet of ombitasvirr, paritaprevirr and ritonavir.The former is HCV NS5A inhibitor, the middle is HCV NS3 / 4A protease inhibitor, and the latter is CYP3A inhibitor. It is combined with ribavirin for the treatment of chronic hepatitis C virus (HCV) infection without cirrhosis. The recommended dose is once a day for breakfast and 2 tablets per day.
【分类号】：R978.7
，

本文编号：2046463